ABOUT QURETECH BIO

QureTech Bio’s vision is to develop first-line drugs to combat infectious diseases and the occurrence of antibiotic resistance.

QureTech Bio was founded in 2010 to commercialize world-leading research from groups based at Umeå University, Sweden, and Washington University, St Louis, USA. Since the foundation, several key persons have joined the company either as board members, researchers, or scientific advisors.

The company’s development programs are partly based on research funded by academic research grants. The company has also received soft funding from Umeå Biotech Incubator, the European Union Horizon 2020 program SME Instrument Phase 1, Swelife (a strategic innovation program funded by the Swedish innovation agency Vinnova), and by the ENABLE-2 program (funded by Vinnova).

Infographic: Quretech Bio wants to combat infectious diseases

MANAGEMENT TEAM

Helén Fält
CEO

Fredrik Almqvist
Research director

Sven Bergström
Chairman

Jörgen Johansson
Co-founder

Annica Rönnbäck
COO

BOARD OF DIRECTORS

Sven Bergström
Chairman of the board

Christina Stallings
Vice chairman

Fredrik Almqvist
Board member

Jörgen Johansson
Deputy board member

Scott Hultgren
Deputy board member/CSO

ADVISORY BOARD

Karin Meyer
Center for Translational Research

Lars Gunneflo
Life Science Consultant

Matthew Chapman
Professor

SCIENTIFIC STAFF

Mari Bonde
Senior Scientist, Molecular biology

Souvik Sarkar
Senior Scientist, Chemisty

Hasan Tükenmez
Senior Scientist, Molecular biology

AFFILIATED SCIENTIST

Fredrik Almqvist
Professor

Sven Bergström
Professor

Jörgen Johansson
Professor

Scott Hultgren
Professor

Christina Stallings
Professor

Michael Caparon
Professor

Ana Flores-Mireles
Assistant Professor

Björn Olsen
Professor

Matthew Chapman
Professor

Jerry Pinkner
M.S.